In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Legend Biotech Corp (NASDAQ:LEGN) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 ...

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate ...

In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

NASDAQ:LEGN opened at $40.03 on Monday. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. Legend Biotech has a 1 year low of $38.60 and a 1 year ...

On Tuesday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $44.62 which represents a slight increase of $1.01 or 2.32% from the prior close of $43.61. The stock opened at $45 ...

Below is Validea's guru fundamental report for LEGEND BIOTECH CORP (ADR) (LEGN). Of the 22 guru strategies we follow, LEGN rates highest using our P/B Growth Investor model based on the published ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk ...